Endocrine Abstracts

Background/Aims: More young people with gender dysphoria are undergoing hormonal intervention with GnRHa treatment. The impact on bone density is not known in the very young transgender adolescents, with guidelines mentioning that Bone Mineral Density (BMD) should be monitored without a suggestion on how. This study aimed to investigate whether there were any changes in BMD or Bone Mineral Apparent Density (BMAD) whilst on GnRHa therapy.Methods: A retros...

To elucidate biochemical evidence for follicular and oocyte maturation, inhibin-A, inhibin-B and activin-A concentrations were measured in 200 follicular fluid samples from follicles ranging from 10.2mm to 36mm in diameter. Inhibin-A concentrations varied from 7.93-436 ng/ml with a mean value was 40.1ng/ml; Inhibin B concentrations varied from 9.7-786 ng/ml with a mean value of 187.3ng/ml; Activin A concentrations varied from 1.73-267.9 ng/ml with a mean value of 40.3ng/ml. Ex...

Background: Being little known about the biochemistry behind the follicular content or granulosa cells surrounding a mature oocyte in Assisted Reproductive Technology, our study set up to investigate the changes in steroid and cytokines' productions by cultured granulosa cells (GC) taken from individual follicles from women undergoing Controlled Ovarian Hyperstimulation (COH).MATERIALS AND METHODS: Granulosa cells isolated from 75 individual follicles we...

Introduction: In the UK, the fasting plasma concentrations of a panel of gut hormones (vasoactive intestinal peptide (VIP), gastrin, pancreatic polypeptide, glucagon and somatostatin as well as chromogranin A) are frequently measured during the evaluation of patients who have confirmed or clinically suspected neuroendocrine tumours (NETs). However, elevated concentrations of these hormones are sometimes also detected in patients who have no other evidence of a NET. We sought t...

Background: Recombinant human growth hormone (r-hGH) has been used for more than 30 years and indications for r-hGH have multiplied worldwide. There has been concern that it might raise mortality, but published data are limited.Methods: The cohort comprised of 3902 UK patients over 18 years of age in 2009, treated with childhood r-hGH at all the major UK growth centres. The total European cohort was 24 232 from eight countries (including the UK), with > ...

Introduction: Adolescents with persistent gender dysphoria (GD) receive GnRH analogues to achieve pubertal arrest. It is unclear whether this is adequate to achieve biochemical suppression of gonadotrophin (LH, FSH) and sex hormone production.Methods: Gonadotrophins, testosterone and oestradiol were measured in GD patients (15–18 years) before and after monthly Gonapeptyl treatment (3.75 mg i.m.). Patients administered other analogues and/or cross-s...

Introduction: Clinical features of severe headache, vision loss, and papilledema; normal neuroimaging and elevated opening pressure on lumbar puncture are diagnostic of idiopathic intracranial hypertensions (IIH) or pseudotumor cerebri. Etiology is often attributed to obesity in young female patients. We present a rare case of Pseudotumor cerebri in a non-obese female patient with severe hypocalcemia.Case: A 26 year old Hispanic female patient with past ...

Growth hormone treatment (GHT) is used to improve height, and potentially quality of life (QOL), in children with abnormal growth patterns. Previous QOL research suggests children with acquired growth hormone deficiency (AGHD) benefit more from GHT than those treated for other conditions.The aim was to determine child and parent reported QOL change over 1 year depending on GHT and diagnosis.One hundred and twenty-two children (mean...

Background: The National Institute for Clinical Excellence (NICE, 2002) suggests that measurement of quality of life (QOL) is necessary to assess the efficacy of GH treatment (GHT). A pilot study (Sheppard 2006) showed a greater improvement in QOL over the first 6 months of GHT for patients with acquired GH deficiency (AGHD) compared with idiopathic GH deficiency (IGHD).Method: In view of this, a longitudinal research study was set up to measure changes ...

Introduction: Graves’ disease (GD) is the most common cause of thyrotoxicosis with antithyroid drugs (ATD) being first-line management. Consultations and monitoring required for ATD therapy are resource intensive. We evaluated the potential for a digital thyrotoxicosis monitoring pathway (DTP) on GD treatment outcomes and efficiency of care.Methods: We constructed a dashboard using Palantir Foundry to identify patie...